Home » Stocks » CANF

Can-Fite BioPharma Ltd. (CANF)

Stock Price: $2.09 USD -0.09 (-4.13%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
Market Cap 39.76M
Revenue (ttm) 763,000
Net Income (ttm) -14.44M
Shares Out 17.19M
EPS (ttm) -1.20
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $2.09
Previous Close $2.18
Change ($) -0.09
Change (%) -4.13%
Day's Open 2.14
Day's Range 2.06 - 2.16
Day's Volume 405,227
52-Week Range 1.51 - 4.39

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Can-Fite BioPharma (NYSE: CANF) has completed pre-clinical studies demonstrating that a Cannabidiol (CBD)-rich T3/C15 cannabis fraction induces inhibition of liver cancer cell growth. The company's lead...

1 week ago - Benzinga

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite: Cannabis Compound Inhibits Liver Cancer Growth in Preclinical Studies

1 week ago - Business Wire

PETACH TIKVA, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address ...

2 weeks ago - Business Wire

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Reports 2020 Financial Results & Provides Clinical Development Update

3 weeks ago - Business Wire

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®

4 weeks ago - Business Wire

Moderna Inc. (NASDAQ: MRNA), AC Immune SA (NASDAQ: ACIU) and Can-Fite BioPharma Ltd. (NYSE: CANF) were among the early biotech movers Tuesday.

Other stocks mentioned: ACIU, MRNA
1 month ago - Benzinga

Can-Fite Biopharma (CANF) stock is on the rise Tuesday after announcing a $42.7 million distribution rights deal with Ewopharma. The post CANF Stock: Why Are Can-Fite Biopharma Shares Skyrocketing Today?

1 month ago - InvestorPlace

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Signs $42.7 Million Out-Licensing Deal with Ewopharma

1 month ago - Business Wire

CanFite Biopharma Ltd (CANF) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 month ago - Zacks Investment Research

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Enrolls First Patient in Phase II COVID-19 Study Under FDA Protocol

1 month ago - Business Wire

Can-Fite BioPharma (NYSE: CANF) reports new data from Phase 2 trial evaluating namodenoson in advanced liver cancer, including the overall survival of nearly four years in two patients under treatment. ...

1 month ago - Benzinga

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory, c...

1 month ago - Business Wire

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Announces Inhibition of Liver Fibrosis by Cannabis Compounds in Preclinical Studies

2 months ago - Business Wire

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammato...

2 months ago - Business Wire

Can-Fite Biopharma  Ltd. was one of the sponsors for the Benzinga Global Small Cap Conference that took place on December 8-9, 2020.

2 months ago - Benzinga

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Announces Publication of Namodenoson Liver Cancer Study in Peer Reviewed Journal—Cancers

3 months ago - Business Wire

Petach Tikva, Israel--(Newsfile Corp. - January 4, 2021) - Can-Fite BioPharma Ltd. (NYSE: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address...

3 months ago - Newsfile Corp

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammato...

4 months ago - Business Wire

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Reports on Progress with its Namodenoson NASH Program

4 months ago - Business Wire

Can-Fite BioPharma Ltd. (CANF) CEO Pnina Fishman on Q3 2020 Results - Earnings Call Transcript

4 months ago - Seeking Alpha

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Reports Third Quarter 2020 Financial Results & Provides Clinical Update

4 months ago - Business Wire

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite's Namodenoson Abstract Selected as ‘Best of The Liver Meeting ‘ in the NASH Category of the American Association of Liver Diseases (AASLD)

4 months ago - Business Wire

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite to Conduct Investor Call to Review Q3 Results and Provide Business Update on Monday, November 30, 2020 at 9:15 a.m. ET

4 months ago - Business Wire

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Presented NASH Phase II Namodenoson Data at a Late Breaking Session of AASLD Conference

5 months ago - Business Wire

With the pandemic drawing much attention toward biotech stocks, there are some interesting ideas among in the small-cap field, but only if you understand the severe risks involved. The post 7 Biotech Pe...

Other stocks mentioned: FPRX, GTBP, IFRX, TNXP, VTVT, VXRT
5 months ago - InvestorPlace

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite to Present its NASH Program in Fireside Chat at the H.C. Wainwright 6th Annual Israel Conference on November 12, 2020

5 months ago - Business Wire

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite to Host Conference Call to Update Shareholders on Positive Interim Results of its Phase III Psoriasis Study on October 15, 2020

6 months ago - Business Wire

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammato...

6 months ago - Business Wire

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Selected to Deliver Late-Breaking Presentation on Namodenoson’s Treatment of NASH at American Association for the Study of Liver Diseases

6 months ago - Business Wire

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite to Participate in Two BioPharma Partnering Conferences

6 months ago - Business Wire

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite to Present at H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020

7 months ago - Business Wire

PETACH TIKVA, Israel--(BUSINESS WIRE)--FDA Clears Can-Fite to Commence Phase II COVID-19 Study

7 months ago - Business Wire

Can-Fite BioPharma Ltd. (CANF) CEO Pnina Fishman on Q2 2020 Results - Earnings Call Transcript

7 months ago - Seeking Alpha

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, li...

7 months ago - Business Wire

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Receives Notification of Patent Grant from European Patent Office for Namodenoson in the Treatment of NASH

7 months ago - Business Wire

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite to Conduct Investor Call to Review Q2 Results and Provide Business Update on Thursday, August 27, 2020 at 4:15 p.m. ET

7 months ago - Business Wire

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Submits Investigational New Drug Application to U.S. FDA for COVID-19 Phase II Study

8 months ago - Business Wire

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Completes Development of an Assay to Identify Clinically Active Cannabis Derived Compounds

8 months ago - Business Wire

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Completes Phase II COVID-19 Protocol Based on FDA Guidance, Plans to File IND Shortly

9 months ago - Business Wire

Can-Fite BioPharma Ltd. (CANF) CEO Pnina Fishman on Q1 2020 Results - Earnings Call Transcript

10 months ago - Seeking Alpha

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 27th

Other stocks mentioned: ATXI, GFI, MN
11 months ago - Zacks Investment Research

As the COVID-19 pandemic continues to ravage the globe, having claimed over 115,000 lives, health care companies have are pursuing diagnostics tests, potential vaccines and therapies.

Other stocks mentioned: ATHX, BCRX, BIOC
1 year ago - Benzinga

Can-Fite BioPharma (NYSE: CANF) shares were trading higher on Tuesday, after the company announced it achieved its main study endpoint in phase 2 NASH study with Namodenoson were dose-dependent.

1 year ago - Benzinga

The following are the latest biotech announcements from late Thursday and Friday morning on the development of products targeting the coronavirus.

Other stocks mentioned: AYTU, ENTA, LJPC, LLY, OPK, RHHBY
1 year ago - Benzinga

Can-Fite (CANF) announces plans to explore piclidenoson for the treatment of coronavirus.

1 year ago - Zacks Investment Research

PETACH TIKVA, Israel, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that...

1 year ago - GlobeNewsWire

Can-Fite BioPharma Ltd CANF 3.77% , an Israeli biotechnology company with a pipeline of proprietary compounds in Phase 2 and 3 clinical development stage that address autoimmune-inflammatory and canc...

1 year ago - Benzinga

Israeli biotechnology company Can-Fite BioPharma Ltd. (NYSE: CANF) said Monday that its drug candidate Piclidenoson for the treatment of osteoarthritis in mammals has been granted Patent No.

1 year ago - Benzinga

Biotechnology company Can-Fite BioPharma Ltd. (NYSE: CANF) announced Tuesday it has partnered with the medical cannabis company Univo Pharmaceuticals to work on developing cannabinoid-based pharmaceutic...

1 year ago - Benzinga

Shares of Can-Fite Biopharma Ltd. CANF, -2.05% soared 18% in active premarket trading Tuesday, after the Israel-based drug development company announced a collaboration agreement with Israeli medical ca...

1 year ago - Market Watch

About CANF

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver and inflammatory disease, COVID-19 and erectile dysfunction. The company's lead drug candidate CF101 (Piclidenoson), which is in Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops CF102 (Namodenoson) that is completed Phase II clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase II trial f... [Read more...]

Industry
Biotechnology
Founded
1994
CEO
Pnina Fishman
Employees
8
Stock Exchange
NYSEAMERICAN
Ticker Symbol
CANF
Full Company Profile

Financial Performance

In 2020, CANF's revenue was 763,000, a decrease of -62.45% compared to the previous year's 2.03 million. Losses were -14.44 million, 14.4% more than in 2019.

Financial numbers in millions ILS.
Financial Statements

Analyst Forecasts

According to one analyst, the rating for CANF stock is "Buy" and the 12-month stock price forecast is 5.00.

Price Target
$5.00
Analyst Consensus: Buy